Results 211 to 220 of about 48,011 (239)
Some of the next articles are maybe not open access.
Extended platelet transfusion in bleeding patients with platelet transfusion refractoriness
Transfusion and Apheresis Science, 2023Tatiana, Fernández-Barge +6 more
openaire +2 more sources
A meta-analysis of risk factors associated with platelet transfusion refractoriness
International journal of hematology, 2023Xiaofei Song +4 more
semanticscholar +1 more source
Alloimmunization and Platelet Transfusion Refractoriness
1993Since over 20 years platelet transfusions are established therapy allowing prolonged survival of patients with hematologic and hemato-oncologic diseases.
openaire +1 more source
Strategies for managing refractoriness to platelet transfusions.
Current hematology reports, 2003The availability of platelet transfusions made possible intensive, myelosuppressive therapy. Chronic transfusion support is often complicated by refractoriness to platelet transfusions characterized by inadequate post-transfusion platelet count increments. Refractoriness is most commonly associated with a variety of clinical factors.
Maria E, Dan, Charles A, Schiffer
openaire +1 more source
Refractoriness to Platelet Transfusions
American Journal of Clinical Pathology, 1989openaire +2 more sources
Challenge of Alloimmunization and Refractoriness to Platelet Transfusion
1997Alloimmunization and refractoriness to platelet transfusion remains the major problem following repeated platelet transfusions. Approaches to donor selection for alloimmunized recipients include a variety of strategies for HLA matching and platelet crossmatching of random donor units of platelet concentrates as a means of identifying new compatible ...
openaire +1 more source
[Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Nihon rinsho. Japanese journal of clinical medicine, 1997Platelet transfusion recipients become alloimmunized to foreign HLA and HPA antigens, impairing their responses to further platelet transfusions (platelet transfusion refractoriness; PTR). Anti-HLA and HPA antibodies account for the majority of clinically significant alloimmunizations.
openaire +1 more source